Cell :复旦教授破译TET2蛋白三维结构,有望用于白血病药物研发

2013-12-09 佚名 生物探索

经过逾4年的研究,复旦大学生物医学研究院徐彦辉课题组首次成功解析了哺乳动物骨髓造血关键蛋白TET2的三维结构,这将对血液肿瘤(即血癌、白血病)治疗性药物的开发具有重大意义。上述成果昨日(6日)已在线发表于国际顶级学术期刊《细胞》杂志上,引起世界同行广泛关注。哺乳动物TET蛋白家族有3个成员,即TET1蛋白、TET2蛋白和TET3蛋白。TET蛋白在哺乳动物发育和骨髓造血等关键生命过程中,扮演至关重

经过逾4年的研究,复旦大学生物医学研究院徐彦辉课题组首次成功解析了哺乳动物骨髓造血关键蛋白TET2的三维结构,这将对血液肿瘤(即血癌、白血病)治疗性药物的开发具有重大意义。上述成果昨日(6日)已在线发表于国际顶级学术期刊《细胞》杂志上,引起世界同行广泛关注。【原文下载

哺乳动物TET蛋白家族有3个成员,即TET1蛋白、TET2蛋白和TET3蛋白。TET蛋白在哺乳动物发育和骨髓造血等关键生命过程中,扮演至关重要的角色。若TET蛋白失去活性,会导致各种疾病,尤其是血癌。2009年以来,全球至少有数十家著名研究机构都在研究TET蛋白的三维结构,以求有所突破,但始终未有结果,而徐彦辉课题组的成果及时、有效地填补了这一空白。

蛋白结构影响遗传基因

据悉,人体遗传物质DNA上有一种甲基化特殊标记。一旦甲基化标记位点紊乱,就会导致如血癌等各种疾病。有趣的是,哺乳动物在发育过程中,体内会根据需要自动调节(去除或添加) DNA上的甲基化标记。科学界此前一直困扰于甲基化标记的“去除”机制。直至2009年,研究发现哺乳动物体内的TET蛋白,对甲基化标记“去除”起了关键作用。

但是相关标记,又如何被TET蛋白添加到DNA上去?四年多前,徐彦辉课题组开展了对这一热点的追踪研究,如今终于解开世界难题。他们运用X射线晶体学等研究方法,获得了TET2蛋白和DNA两者结合在一起的三维结构,结果发现TET2蛋白非常“聪明”,它能够自动识别、找到甲基化标记,并会把甲基化标记修饰过的DNA翻转到TET2蛋白的内部,并在内部铁离子等帮助下,通过氧化反应,将这些标记逐步添加到DNA甲基化标记上。

TET1成"致病帮凶"

徐彦辉表示,原来血癌患者血液中含有多种TET2蛋白突变,正是这些突变影响了TET2蛋白的活性,导致它"消极怠工",无所作为,最终引起疾病发生。而TET2蛋白的"同胞兄弟"TET1,在急性髓细胞性白血病形成过程中过分活跃,扮演了“致病帮凶”的角色。

徐彦辉解释说,上述研究成果的重大意义在于,可以通过对TET2蛋白三维结构的分析、计算机模拟、高通量的化合物筛选等方法,找到能够激活TET2蛋白,或抑制TET1蛋白活性的相关药物,从而为人类最终战胜白血病等作出贡献。

原文出处

Lulu Hu, Ze Li, Jingdong Cheng, Qinhui Rao, Wei Gong, Mengjie Liu, Yujiang Geno Shi, Jiayu Zhu, Ping Wang, Yanhui Xu.Crystal Structure of TET2-DNA Complex: Insight into TET-Mediated 5mC Oxidation.Cell 2013 Dec.05【原文下载

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958962, encodeId=1145195896225, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 05 08:06:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734791, encodeId=4a891e3479163, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Wed May 28 21:06:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011153, encodeId=54932011153bd, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Oct 15 23:06:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868722, encodeId=6f581868e22cc, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 07 00:06:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027532, encodeId=a2e7202e532f1, content=<a href='/topic/show?id=1c14e1796aa' target=_blank style='color:#2F92EE;'>#白血病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71796, encryptionId=1c14e1796aa, topicName=白血病药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue Aug 05 04:06:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800152, encodeId=0b8518001525e, content=<a href='/topic/show?id=47e3e1795c3' target=_blank style='color:#2F92EE;'>#白血病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71795, encryptionId=47e3e1795c3, topicName=白血病药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Mon Jul 14 10:06:00 CST 2014, time=2014-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299767, encodeId=20931299e6776, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301404, encodeId=075213014042e, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446525, encodeId=99171446525de, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538426, encodeId=2c361538426ee, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=)]
    2014-04-05 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958962, encodeId=1145195896225, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 05 08:06:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734791, encodeId=4a891e3479163, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Wed May 28 21:06:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011153, encodeId=54932011153bd, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Oct 15 23:06:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868722, encodeId=6f581868e22cc, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 07 00:06:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027532, encodeId=a2e7202e532f1, content=<a href='/topic/show?id=1c14e1796aa' target=_blank style='color:#2F92EE;'>#白血病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71796, encryptionId=1c14e1796aa, topicName=白血病药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue Aug 05 04:06:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800152, encodeId=0b8518001525e, content=<a href='/topic/show?id=47e3e1795c3' target=_blank style='color:#2F92EE;'>#白血病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71795, encryptionId=47e3e1795c3, topicName=白血病药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Mon Jul 14 10:06:00 CST 2014, time=2014-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299767, encodeId=20931299e6776, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301404, encodeId=075213014042e, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446525, encodeId=99171446525de, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538426, encodeId=2c361538426ee, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958962, encodeId=1145195896225, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 05 08:06:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734791, encodeId=4a891e3479163, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Wed May 28 21:06:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011153, encodeId=54932011153bd, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Oct 15 23:06:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868722, encodeId=6f581868e22cc, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 07 00:06:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027532, encodeId=a2e7202e532f1, content=<a href='/topic/show?id=1c14e1796aa' target=_blank style='color:#2F92EE;'>#白血病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71796, encryptionId=1c14e1796aa, topicName=白血病药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue Aug 05 04:06:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800152, encodeId=0b8518001525e, content=<a href='/topic/show?id=47e3e1795c3' target=_blank style='color:#2F92EE;'>#白血病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71795, encryptionId=47e3e1795c3, topicName=白血病药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Mon Jul 14 10:06:00 CST 2014, time=2014-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299767, encodeId=20931299e6776, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301404, encodeId=075213014042e, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446525, encodeId=99171446525de, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538426, encodeId=2c361538426ee, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=)]
    2014-10-15 yhy100200
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958962, encodeId=1145195896225, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 05 08:06:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734791, encodeId=4a891e3479163, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Wed May 28 21:06:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011153, encodeId=54932011153bd, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Oct 15 23:06:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868722, encodeId=6f581868e22cc, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 07 00:06:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027532, encodeId=a2e7202e532f1, content=<a href='/topic/show?id=1c14e1796aa' target=_blank style='color:#2F92EE;'>#白血病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71796, encryptionId=1c14e1796aa, topicName=白血病药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue Aug 05 04:06:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800152, encodeId=0b8518001525e, content=<a href='/topic/show?id=47e3e1795c3' target=_blank style='color:#2F92EE;'>#白血病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71795, encryptionId=47e3e1795c3, topicName=白血病药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Mon Jul 14 10:06:00 CST 2014, time=2014-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299767, encodeId=20931299e6776, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301404, encodeId=075213014042e, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446525, encodeId=99171446525de, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538426, encodeId=2c361538426ee, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1958962, encodeId=1145195896225, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 05 08:06:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734791, encodeId=4a891e3479163, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Wed May 28 21:06:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011153, encodeId=54932011153bd, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Oct 15 23:06:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868722, encodeId=6f581868e22cc, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 07 00:06:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027532, encodeId=a2e7202e532f1, content=<a href='/topic/show?id=1c14e1796aa' target=_blank style='color:#2F92EE;'>#白血病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71796, encryptionId=1c14e1796aa, topicName=白血病药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue Aug 05 04:06:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800152, encodeId=0b8518001525e, content=<a href='/topic/show?id=47e3e1795c3' target=_blank style='color:#2F92EE;'>#白血病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71795, encryptionId=47e3e1795c3, topicName=白血病药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Mon Jul 14 10:06:00 CST 2014, time=2014-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299767, encodeId=20931299e6776, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301404, encodeId=075213014042e, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446525, encodeId=99171446525de, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538426, encodeId=2c361538426ee, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1958962, encodeId=1145195896225, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 05 08:06:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734791, encodeId=4a891e3479163, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Wed May 28 21:06:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011153, encodeId=54932011153bd, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Oct 15 23:06:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868722, encodeId=6f581868e22cc, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 07 00:06:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027532, encodeId=a2e7202e532f1, content=<a href='/topic/show?id=1c14e1796aa' target=_blank style='color:#2F92EE;'>#白血病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71796, encryptionId=1c14e1796aa, topicName=白血病药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue Aug 05 04:06:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800152, encodeId=0b8518001525e, content=<a href='/topic/show?id=47e3e1795c3' target=_blank style='color:#2F92EE;'>#白血病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71795, encryptionId=47e3e1795c3, topicName=白血病药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Mon Jul 14 10:06:00 CST 2014, time=2014-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299767, encodeId=20931299e6776, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301404, encodeId=075213014042e, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446525, encodeId=99171446525de, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538426, encodeId=2c361538426ee, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1958962, encodeId=1145195896225, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 05 08:06:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734791, encodeId=4a891e3479163, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Wed May 28 21:06:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011153, encodeId=54932011153bd, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Oct 15 23:06:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868722, encodeId=6f581868e22cc, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 07 00:06:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027532, encodeId=a2e7202e532f1, content=<a href='/topic/show?id=1c14e1796aa' target=_blank style='color:#2F92EE;'>#白血病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71796, encryptionId=1c14e1796aa, topicName=白血病药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue Aug 05 04:06:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800152, encodeId=0b8518001525e, content=<a href='/topic/show?id=47e3e1795c3' target=_blank style='color:#2F92EE;'>#白血病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71795, encryptionId=47e3e1795c3, topicName=白血病药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Mon Jul 14 10:06:00 CST 2014, time=2014-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299767, encodeId=20931299e6776, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301404, encodeId=075213014042e, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446525, encodeId=99171446525de, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538426, encodeId=2c361538426ee, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=)]
    2013-12-11 lqvr
  8. [GetPortalCommentsPageByObjectIdResponse(id=1958962, encodeId=1145195896225, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 05 08:06:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734791, encodeId=4a891e3479163, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Wed May 28 21:06:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011153, encodeId=54932011153bd, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Oct 15 23:06:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868722, encodeId=6f581868e22cc, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 07 00:06:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027532, encodeId=a2e7202e532f1, content=<a href='/topic/show?id=1c14e1796aa' target=_blank style='color:#2F92EE;'>#白血病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71796, encryptionId=1c14e1796aa, topicName=白血病药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue Aug 05 04:06:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800152, encodeId=0b8518001525e, content=<a href='/topic/show?id=47e3e1795c3' target=_blank style='color:#2F92EE;'>#白血病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71795, encryptionId=47e3e1795c3, topicName=白血病药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Mon Jul 14 10:06:00 CST 2014, time=2014-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299767, encodeId=20931299e6776, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301404, encodeId=075213014042e, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446525, encodeId=99171446525de, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538426, encodeId=2c361538426ee, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1958962, encodeId=1145195896225, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 05 08:06:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734791, encodeId=4a891e3479163, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Wed May 28 21:06:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011153, encodeId=54932011153bd, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Oct 15 23:06:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868722, encodeId=6f581868e22cc, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 07 00:06:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027532, encodeId=a2e7202e532f1, content=<a href='/topic/show?id=1c14e1796aa' target=_blank style='color:#2F92EE;'>#白血病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71796, encryptionId=1c14e1796aa, topicName=白血病药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue Aug 05 04:06:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800152, encodeId=0b8518001525e, content=<a href='/topic/show?id=47e3e1795c3' target=_blank style='color:#2F92EE;'>#白血病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71795, encryptionId=47e3e1795c3, topicName=白血病药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Mon Jul 14 10:06:00 CST 2014, time=2014-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299767, encodeId=20931299e6776, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301404, encodeId=075213014042e, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446525, encodeId=99171446525de, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538426, encodeId=2c361538426ee, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=)]
    2013-12-11 neurowu
  10. [GetPortalCommentsPageByObjectIdResponse(id=1958962, encodeId=1145195896225, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 05 08:06:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734791, encodeId=4a891e3479163, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Wed May 28 21:06:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011153, encodeId=54932011153bd, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Oct 15 23:06:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868722, encodeId=6f581868e22cc, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 07 00:06:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027532, encodeId=a2e7202e532f1, content=<a href='/topic/show?id=1c14e1796aa' target=_blank style='color:#2F92EE;'>#白血病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71796, encryptionId=1c14e1796aa, topicName=白血病药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue Aug 05 04:06:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800152, encodeId=0b8518001525e, content=<a href='/topic/show?id=47e3e1795c3' target=_blank style='color:#2F92EE;'>#白血病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71795, encryptionId=47e3e1795c3, topicName=白血病药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Mon Jul 14 10:06:00 CST 2014, time=2014-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299767, encodeId=20931299e6776, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301404, encodeId=075213014042e, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446525, encodeId=99171446525de, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538426, encodeId=2c361538426ee, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Wed Dec 11 02:06:00 CST 2013, time=2013-12-11, status=1, ipAttribution=)]
    2013-12-11 saikp

相关资讯

NEJM:白血病新药与心血管风险监测

近日,有关慢性髓性白血病的治疗遭遇意想不到的挫折:经酪氨酸激酶抑制剂药物普纳替尼和尼洛替尼治疗后,患者出现了严重心血管事件。BCR-ABL靶向蛋白激酶抑制剂药物曾被视为慢性髓性白血病(CML)治疗领域的革命性药物,同时还被确立为癌症药物研发的典范。 2001年,FDA批准了首款该类酪氨酸激酶抑制剂药物伊马替尼。伊马替尼一开始是作为血小板源性生长因子受体抑制剂的系列复合

FDA批准Gazyva与苯丁酸氮芥联合治疗慢性淋巴细胞白血病

11月1日,美国食品药品管理局(FDA)批准Gazyva(Obinutuzumab)与苯丁酸氮芥联合用药共同治疗先前未经处理的慢性淋巴细胞性白血病(CLL)。 CLL是一种血液及骨髓疾病,该疾病通常会缓慢恶化。根据美国国家癌症研究所预测,今年将有15680美国人被确诊患有这种疾病且4580人将会死于这种疾病。 Gazyva是通过帮助免疫系统中的某些细胞来攻击肿瘤细胞发挥其作用。

韩国三星工厂导致员工罹患白血病

两年前,一则CNN新闻报导援引由三星(Samsung)委托进行的调查报告指出,该公司位于南韩的厂房并无导致员工健康疑虑的风险;该项由Environ所进行的研究结果表示,没有科学证据显示三星工厂与员工罹患血癌风险增加有关连。但是在当时,Environ也没有提供任何支持该结论的相关资讯,似乎有用“商业机密”这样的老藉口来隐匿事实的嫌疑。 而根据最近一篇美联社(AP)报导指出,南韩某法院调查结

Angew Chem:一种新活性物质可抑制白血病细胞分裂

德国弗赖堡大学日前发表研究公报,称发现了一种新的活性物质,可以抑制白血病细胞分裂,而且有望在抗癌治疗中发挥重要作用。 这种被称为XD14的活性物质可以抑制BET蛋白家族中的几种蛋白功能。BET蛋白也称为表观遗传识别蛋白,可以识别细胞组蛋白中的表观遗传学信息变化,并传递激发细胞分裂等的信号。以白血病为例,血细胞内BET蛋白的基因突变会干扰这种信号传输,导致病变细胞不受控

FDA宣布暂停销售白血病治疗药物ponatinib

10月31日,美国食品药品管理局(FDA)宣布,鉴于与普纳替尼(ponatinib)相关的“危及生命的血栓和血管重度狭窄”风险,FDA已经要求生产商暂停这种白血病治疗药物的销售和推广。这距离普纳替尼加速审批还不到1年的时间。去年12月该药获准用于对既往酪氨酸激酶抑制剂(TKI)治疗耐药或不耐受的慢性期、加速期或急变期慢性粒细胞性白血病(CML),以及对既往TKI治疗耐药或不耐受的费城染色体阳性急性

上海医务人员为白血病患者捐献造血干细胞

12日,复旦大学附属中山医院秦刚医生完成了第一日的造血干细胞采集,他成为了该院第一位成功捐献造血干细胞的医务人员,也是上海市第288例造血干细胞捐献者。 他将于12日和13日采集两次达到足量的造血干细胞供临床治疗使用。 申城初冬的朝阳,因着一份爱显得暖意融融,一位白衣天使自愿捋袖无私捐献出自己的造血干细胞;而在另一家医院,一位白血病患者因此而看到了生命的曙光。 据了解,目前,